Corticosteroid-dependent hypertension: Environmental influences

Swiss Medical Weekly

Volumn 134, Issue 1-2, 2004, Pages 4-13

  Odermatt, Alex ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

11beta hydroxysteroid dehydrogenase; Aldosterone; Cortisol; Endocrine disruptor; Environmental chemical; Hypertension; Sodium

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ABIETIC ACID; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DITHIOCARBAMIC ACID; FLAVANONE DERIVATIVE; FUROSEMIDE; GENISTEIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCYRRHETINIC ACID; GLYCYRRHIZA EXTRACT; GOSSYPOL; MINERALOCORTICOID RECEPTOR; SODIUM; SODIUM CHANNEL;

ALDOSTERONE RELEASE; BLOOD PRESSURE MEASUREMENT; CORTICOSTEROID THERAPY; ENVIRONMENTAL FACTOR; ESSENTIAL HYPERTENSION; GENETIC DISORDER; GRAPEFRUIT JUICE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; ONSET AGE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM TRANSPORT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SODIUM BALANCE; SODIUM RETENTION; WATER RETENTION;

EID: 1642454910     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. White PC, Mune T, Agarwal AK. 11beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997;18:135-56.
2. Stewart PM, Krozowski ZS. 11beta-Hydroxysteroid dehydrogenase. Vitam Horm 1999;57:249-324.
3. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
4. +) channel cell surface expression. Embo J 2001;20:7052-9.
5. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-75.
6. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A 1992;89:8327-31.
7. Curnow KM, Slutsker L, Vitek J, Cole T, Speiser PW, New MI, et al. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A 1993;90:4552-6.
8. Kagimoto M, Winter JS, Kagimoto K, Simpson ER, Waterman MR. Structural characterization of normal and mutant human steroid 17alpha-hydroxylase genes: molecular basis of one example of combined 17alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol 1988;2:564-70.
9. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. Nat Genet 1995;10:394-9.
10. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995;80:2263-6.
11. New MI, Wilson RC. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci U S A 1999;96:12790-7.
12. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979;49:757-64.
13. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000;289:119-23.
14. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994;79:407-14.
15. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995;11:76-82.
16. Hansson JH, Schild L, Lu Y, Wilson TA, Gautschi I, Shimkets R, et al. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci U S A 1995;92:11495-9.
17. + channel by Nedd4 in Liddle's syndrome. J Clin Invest 1999;103:667-73.
18. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996;12:248-53.
19. Hoyer PB. Reproductive toxicology: current and future directions. Biochem Pharmacol 2001;62:1557-64.
20. Lathers CM. Endocrine disruptors: a new scientific role for clinical pharmacologists? Impact on human health, wildlife, and the environment. J Clin Pharmacol 2002;42:7-23.
21. Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ, Habrioux G. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities. Life Sci 2001;68:751-61.
22. Krazeisen A, Breitling R, Moller G, Adamski J. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5. Mol Cell Endocrinol 2001;171:151-62.
23. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557-72.
24. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced foetal growth. Diabetologia 1993;36:62-7.
25. Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. J Hypertens 1996;14:935-41.
26. Barker DJ. Foetal origins of coronary heart disease. BMJ 1995;311:171-4.
27. Ounsted M, Ounsted C. Rate of intra-uterine growth. Nature 1968;220:599-600.
28. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Foetal nutrition and cardiovascular disease in adult life. Lancet 1993;341:938-41.
29. Fowden AL. Endocrine regulation of foetal growth. Reprod Fertil Dev 1995;7:351-63.
30. Goland RS, Jozak S, Warren WB, Conwell IM, Stark RI, Tropper PJ. Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded foetuses. J Clin Endocrinol Metab 1993;77:1174-9.
31. Stewart PM, Rogerson FM, Mason JI. Type 2 11beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and foetal membranes: its relationship to birth weight and putative role in foetal adrenal steroidogenesis. J Clin Endocrinol Metab 1995;80:885-90.
32. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993;341:339-41.
33. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest 1998;101:2174-81.
34. Lesage J, Blondeau B, Grino M, Breant B, Dupouy JP. Maternal undernutrition during late gestation induces fetal overexposure to glucocorticoids and intrauterine growth retardation, and disturbs the hypothalamo-pituitary adrenal axis in the newborn rat. Endocrinology 2001;142:1692-702.
35. Bertram C, Trowern AR, Copin N, Jackson AA, Whorwood CB. The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero. Endocrinology 2001;142:2841-53.
36. Barrett JR: Soy and children's health: a formula for trouble. Environ Health Perspect 2002;110:A294-6.
37. Mesiano S, Katz SL, Lee JY, Jaffe RB. Phytoestrogens alter adrenocortical function: genistein and daidzein suppress glucocorticoid and stimulate androgen production by cultured adrenal cortical cells. J Clin Endocrinol Metab 1999;84:2443-8.
38. Badger TM, Ronis MJ, Hakkak R, Rowlands JC, Korourian S. The health consequences of early soy consumption. J Nutr 2002;132:559S-65S.
39. Redon J. Hypertension in obesity. Nutr Metab Cardiovasc Dis 2001;11:344-53.
40. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum?" Lancet 1997;349:1210-3.
41. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, et al. Subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003;88:2738-44.
42. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70.
43. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003;112:83-90.
44. Bhathena SJ, Velasquez MT: Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 2002;76:1191-201.
45. Schweizer RAS, Atanasov AG, Frey BM, Odermatt A. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol 2003;212:41-9.
46. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycaemic mice strains. Endocrinology 2003;144:4755-62.
47. Davis EA, Morris DJ. Medicinal uses of liquorice through the millennia: the good and plenty of it. Mol Cell Endocrinol 1991;78:1-6.
48. Reevers F. Heeft succus liquritiae een genezende werking op de maagzweer? Ned Tijdschr Geneeskd 1946;90:135-7.
49. Molhuysen JA, Gerbrandy J, De Vries LA, DeJong JC, Lenstra JB, Turner KP, et al. A liquorice extract with deoxycortone-like action. Lancet 1950;107:381-6.
50. Turpie AG, Thomson TJ. Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects. Gut 1965;6:591-4.
51. Kageyama Y, Suzuki H, Saruta T. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney. J Endocrinol 1992;135:147-52.
52. Sigurjonsdottir HA, Ragnarsson J, Franzson L, Sigurdsson G. Is blood pressure commonly raised by moderate consumption of liquorice? J Hum Hypertens 1995;9:345-8.
53. Blachley JD, Knochel JP. Tobacco chewer's hypokalemia: licorice revisited. N Engl J Med 1980;302:784-5.
54. de Klerk GJ, Nieuwenhuis MG, Beutler JJ. Hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum. BMJ 1997;314:731-2.
55. Carmines EL. Evaluation of the potential effects of ingredients added to cigarettes. Part 1: cigarette design, testing approach, and review of results. Food Chem Toxicol 2002;40:77-91.
56. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol 1992;263:E1125-1130.
57. Lindsay RS, Lindsay RM, Edwards CR, Seckl JR. Inhibition of 11-beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension 1996;27:1200-4.
58. Ferrari P, Sansonnens A, Dick B, Frey FJ. In Vivo 11beta-HSD-2 Activity: Variability, Salt-Sensitivity, and Effect of Licorice. Hypertension 2001;38:1330-6.
59. Odermatt A, Arnold P, Frey FJ. The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. J Biol Chem 2001;276:28484-92.
60. Bernardi M, D'Intino PE, Trevisani F, Cantelli-Forti G, Raggi MA, Turchetto E, et al. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers. Life Sci 1994;55:863-72.
61. Quinkler M, Johanssen S, Grossmann C, Bahr V, Muller M, Oelkers W, et al. Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. J Clin Endocrinol Metab 1999;84:4165-71.
62. Heilmann P, Buchheim E, Wacker J, Ziegler R. Alteration of the activity of the 11beta-hydroxysteroid dehydrogenase in pregnancy: relevance for the development of pregnancy-induced hypertension? J Clin Endocrinol Metab 2001;86:5222-6.
63. Brown MA, Zammit VC, Mitar DA, Whitworth JA. Renin-aldosterone relationships in pregnancy-induced hypertension. Am J Hypertens 1992;5:366-71.
64. August P, Lenz T, Ales KL, Druzin ML, Edersheim TG, Hutson JM, et al. Longitudinal study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: deviations related to the development of superimposed preeclampsia. Am J Obstet Gynecol 1990;163:1612-21.
65. Elsheikh A, Creatsas G, Mastorakos G, Milingos S, Loutradis D, Michalas S. The renin-aldosterone system during normal and hypertensive pregnancy. Arch Gynecol Obstet 2001;264:182-5.
66. Lee YS, Lorenzo BJ, Koufis T, Reidenberg MM. Grapefruit juice and its flavonoids inhibit 11 beta-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996;59:62-71.
67. Zhang YD, Lorenzo B, Reidenberg MM. Inhibition of 11beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compounds. J Steroid Biochem Mol Biol 1994;49:81-5.
68. Morton MS, Wilcox G, Wahlqvist ML, Griffiths K. Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. J Endocrinol 1994;142:251-9.
69. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342:1209-10.
70. Hult M, Jornvall H, Oppermann UC. Selective inhibition of human type 1 11beta-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett 1998;441:25-8.
71. Esther G, Meyer KV, Vishwanath BS, Frey BM, Frey FJ. Furosemide inhibits 11beta-hydroxysteroid dehydrogenase in vitro and in vivo. Endocrinology 1995;136:1759-65.
72. Fuster D, Escher G, Vogt B, Ackermann D, Dick B, Frey BM, et al. Furosemide inhibits 11beta-hydroxysteroid dehydrogenase type 2. Endocrinology 1998;139:3849-54.
73. Nettis E, Assennato G, Ferrannini A, Tursi A. Type 1 allergy to natural rubber latex and type IV allergy to rubber chemicals in health care workers with glove-related skin symptoms. Clin Exp Allergy 2002;32:441-7.
74. Dalvi RR, Robbins TJ, Williams MK, Deoras DP, Donastorg F, Banks C. Thiram-induced toxic liver injury in male Sprague-Dawley rats. J Environ Sci Health B 1984;19:703-12.
75. Cereda JM, Bernuau J, Degott C, Rueff B, Benhamou JP. Fatal liver failure due to disulfiram. J Clin Gastroenterol 1989;11:98-100.
76. Maita K, Tsuda S, Shirasu Y. Chronic toxicity studies with thiram in Wistar rats and beagle dogs. Fundam Appl Toxicol 1991;16:667-86.
77. Mishra VK, Srivastava MK, Raizada RB. Testicular toxicity in rat to repeated oral administration of tetramethylthiuram disulfide (Thiram). Indian J Exp Biol 1998;36:390-4.
78. Guven K, Deveci E, Akba O, Onen A, de Pomerai D. The accumulation and histological effects of organometallic fungicides Propineb and Maneb in the kidneys of foetus and female rats during pregnancy. Toxicol Lett 1998;99:91-8.
79. Koizumi A, Shiojima S, Omiya M, Nakano S, Sato N, Ikeda M. Acute renal failure anti maneb (manganous ethylenebis [dithiocarbamate]) exposure. JAMA 1979;242:2583-5.
80. Atanasov AG, Tam S, Rocken JM, Baker ME, Odermatt A. Inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by dithiocarbamates. Biochem Biophys Res Commun 2003;308:257-62.
81. Frank N, Christmann A, Frei E. Comparative studies on the pharmacokinetics of hydrophilic prolinedithiocarbamate, sarcosinedithiocarbamate and the less hydrophilic diethyldithiocarbamate. Toxicology 1995;95:113-22.
82. Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, Colditz GA, et al. Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. BMJ 1997;315:396-400.
83. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Ascherio AL, Stampfer MJ. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men. Circulation 1996;94:3246-50.
84. Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996;39:1299-305.
85. San Feliciano A, Gordaliza M, Salinero MA, Miguel del Corral JM. Abietane acids: sources, biological activities, and therapeutic uses. Planta Med 1993;59:485-90.
86. Fernandez MA, Tornos MP, Garcia MD, de las Heras B, Villar AM, Saenz MT. Anti-inflammatory activity of abietic acid, a diterpene isolated from Pimenta racemosa var. grissea. J Pharm Pharmacol 2001;53:867-72.
87. Qian SZ, Wang ZG: Gossypol: a potential antifertility agent for males. Annu Rev Pharmacol Toxicol 1984;24:329-60.
88. Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs 1989;38:333-41.
89. Sang GW, Lorenzo B, Reidenberg MM. Inhibitory effects of gossypol on corticosteroid 11-beta-hydroxysteroid dehydrogenase from guinea pig kidney: a possible mechanism for causing hypokalaemia. J Steroid Biochem Mol Biol 1991;39:169-76.
90. Song D, Lorenzo B, Reidenberg MM. Inhibition of 11beta-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J Lab Clin Med 1992;120:792-7.
91. Guo J, Reidenberg MM. Inhibition of 11beta-hydroxysteroid dehydrogenase by bioflavonoids and their interaction with furosemide and gossypol. J Lab Clin Med 1998;132:32-8.